19 research outputs found

    (The)Effect of aging and intensity of contraction on the mechanisms of muscle fatigue

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(๋ฐ•์‚ฌ)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :์ฒด์œก๊ต์œก๊ณผ,2006.Docto

    Antitumor efficacy of modified E2F-1 depend oncolytic adenovirus and potency of modified HRE enhancer under hypoxia condition

    No full text
    ์˜๊ณผํ•™๊ณผ/์„์‚ฌ2009๋…„ WHO ํ†ต๊ณ„์— ๋”ฐ๋ฅด๋ฉด, ์šฐ๋ฆฌ๋‚˜๋ผ ์•”ํ™˜์ž์˜ ์ƒ์กด์œจ์€ 57.1%๋กœ ๋ฏธ๊ตญ, ์บ๋‚˜๋‹ค ๋“ฑ์˜ ๋‚˜๋ผ์— ๋น„ํ•ด์„œ 10-20% ์ •๋„ ๋‚ฎ์€ ์ƒ์กด์œจ์„ ๋ณด์ด๊ณ  ์žˆ๊ณ , ์ด๋กœ ์ธํ•ด์„œ ์ƒˆ๋กœ์šด ์น˜๋ฃŒ๋ฒ•์˜ ํ•„์š”์„ฑ์ด ์ ์ฐจ ์ปค์ง€๊ณ  ์žˆ๋Š” ํ˜„์‹ค์ด๋‹ค. ์œ ์ „์ž ์น˜๋ฃŒ๋Š” ๊ธฐ์กด ์•” ์น˜๋ฃŒ๋ฒ•์„ ๋Œ€์ฒดํ•˜๊ธฐ์œ„ํ•ด ์ƒˆ๋กญ๊ฒŒ ์—ฐ๊ตฌ๋˜๊ณ ์žˆ๋Š” ์น˜๋ฃŒ๋ฒ•์ด๋ฉฐ, ์œ ์ „์ž ์น˜๋ฃŒ ๋ฐฉ๋ฒ• ์ค‘ ํ•˜๋‚˜์ธ ์ข…์–‘ ์„ ํƒ์  ์‚ด์ƒ ์•„๋ฐ๋…ธ๋ฐ”์ด๋Ÿฌ์Šค๋Š” ์ด์ „์— ๊ฐœ๋ฐœ๋˜์—ˆ๋˜ ๋ณต์ œ ๋ถˆ๋Šฅ ์•„๋ฐ๋…ธ๋ฐ”์ด๋Ÿฌ์Šค์™€ ๋น„๊ตํ–ˆ์„ ๋•Œ ์ข‹์€ ์น˜๋ฃŒ ํšจ๊ณผ์™€ ์•”์„ธํฌ ์‚ด์ƒ์œจ์ด ๋†’๊ฒŒ ๋‚˜ํƒ€๋‚จ์ด ๋ณด๊ณ ๋˜์—ˆ๋‹ค. ๋ณธ ์‹คํ—˜์‹ค์—์„œ ๊ฐœ๋ฐœ๋œ ์ข…์–‘ ์„ ํƒ์  ์‚ด์ƒ ์•„๋ฐ๋…ธ๋ฐ”์ด๋Ÿฌ์Šค์ธ Ad-dE1B19๋Š” ์•ผ์ƒํ˜• ์•„๋ฐ๋…ธ๋ฐ”์ด๋Ÿฌ์Šค์˜ ์œ ์ „์ž ์ค‘ E1B19 kDa์„ ์ œ๊ฑฐํ•œ ๋ฐ”์ด๋Ÿฌ์Šค๋กœ์„œ ๋งค์šฐ ํšจ์œจ์ ์ธ ์•”์„ธํฌ ์‚ด์ƒ๋Šฅ์„ ๋ณด์—ฌ์ฃผ์—ˆ์œผ๋‚˜, ์ •์ƒ ์„ธํฌ๋“ค๋„ ์ฃฝ์ด๋Š” ํ•œ๊ณ„์ ์„ ๊ฐ€์ง€๊ณ  ์žˆ์—ˆ๋‹ค.๋”ฐ๋ผ์„œ ๋ณธ ์—ฐ๊ตฌ์—์„œ๋Š” ์ •์ƒ ์„ธํฌ๊ฐ€ ์•„๋‹Œ ์•”์„ธํฌ๋งŒ์„ ์‚ด์ƒํ•˜๋Š” ํšจ๊ณผ๋ฅผ ์–ป๊ธฐ ์œ„ํ•˜์—ฌ ์•”์„ธํฌ ํŠน์ด์  ์‚ด์ƒ ์•„๋ฐ๋…ธ๋ฐ”์ด๋Ÿฌ์Šค๋ฅผ ์ œ์ž‘ํ•˜์˜€๋‹ค. ์ด๋ฅผ ์œ„ํ•ด์„œ ์•”์„ธํฌ์— ๋งŽ์ด ๋ฐœํ˜„๋˜๋Š” E2F-1 ์ „์‚ฌ์ธ์ž๊ฐ€ ๊ฒฐํ•ฉํ•  ์ˆ˜ ์žˆ๋„๋ก ์žฌ์กฐํ•ฉ๋œ E2F-1 ํ”„๋กœ๋ชจํ„ฐ๋ฅผ ์•„๋ฐ๋…ธ๋ฐ”์ด๋Ÿฌ์Šค์— ๋„ฃ์Œ์œผ๋กœ์จ ์•”์„ธํฌ ํŠน์ด์ ์ธ ์•„๋ฐ๋…ธ๋ฐ”์ด๋Ÿฌ์Šค์˜ ๋ณต์ œ ์กฐ์ ˆ์„ ์œ ๋„ํ•˜์˜€๋‹ค. ์žฌ์กฐํ•ฉ๋œ E2F-1 ํ”„๋กœ๋ชจํ„ฐ ์ค‘, E2F-1์ด ๊ฒฐํ•ฉํ•˜๋Š” ๊ฒฐํ•ฉํ•ต์‹ฌ๋ถ€์œ„์„ ๋ฐ˜๋ณต ์—ผ๊ธฐ ํ˜•ํƒœ(E2Ftr)๋กœ ์กด์žฌํ•  ๋•Œ์— ๋Œ€์กฐ๊ตฐ์ธ E2Ftr๊ฐ€ ์—†๋Š” Ad-E2F-d19๋ณด๋‹ค ๋” ํ–ฅ์ƒ๋œ ํ”„๋กœ๋ชจํ„ฐ ํ™œ์„ฑ์„ ๋ณด์˜€๊ณ  ๊ฒฐ๊ณผ์ ์œผ๋กœ ๋” ๋‚˜์€ ์•”์„ธํฌ ์‚ด์ƒ๋Šฅ์„ ๋‚˜ํƒ€๋ƒˆ๋‹ค. ์ด๋Ÿฌํ•œ ๊ฒฝํ–ฅ์€ cytopathic effect assay๋ฟ๋งŒ์ด ์•„๋‹ˆ๋ผ MTT assay์—์„œ๋„ ๊ด€์ฐฐ๋˜์—ˆ๋‹ค. ๊ทธ๋ฆฌ๊ณ  viral productivity assay๋Š” ์žฌ์กฐํ•ฉ๋œ E2F-1 ํ”„๋กœ๋ชจํ„ฐ์˜ ํ–ฅ์ƒ๋œ ์ „์‚ฌ ํ™œ์„ฑ์œผ๋กœ ์ธํ•ด ์•„๋ฐ๋…ธ๋ฐ”์ด๋Ÿฌ์Šค๊ฐ€ ๋” ๋งŽ์ด ๋ณต์ œ๋˜์—ˆ์Œ์„ ๋ณด์—ฌ์ฃผ์—ˆ๊ณ , ๊ทธ๋กœ์ธํ•ด cytopathic effect assay์™€ MTT assay์—์„œ ๊ด€์ฐฐ๋˜์—ˆ๋˜ ํ–ฅ์ƒ๋œ ์•”์„ธํฌ ์‚ด์ƒ์ด ์ด๋ฃจ์–ด์กŒ์Œ์„ ์•Œ ์ˆ˜ ์žˆ์—ˆ๋‹ค. ํ•˜์ง€๋งŒ E2F-1 ํ”„๋กœ๋ชจํ„ฐ๋Š” ์ €์‚ฐ์†Œ ์กฐ๊ฑด์—์„œ ๊ทธ ํ™œ์„ฑ์ด ๋–จ์–ด์ง„๋‹ค๋Š” ๋ณด๊ณ 1๊ฐ€ ์žˆ์–ด์„œ ์ด๋ฅผ ๊ทน๋ณตํ•˜๋Š” ๊ณผ์ •์ด ํ•„์š”ํ•˜๊ณ , ๋˜ํ•œ ์•”์กฐ์ง์˜ ํŠน์ง• ์ค‘ ํ•˜๋‚˜์ธ ์ €์‚ฐ์†Œ ์กฐ๊ฑด์—์„œ ์•„๋ฐ๋…ธ๋ฐ”์ด๋Ÿฌ์Šค์˜ ์„ ํƒ์  ํ”„๋กœ๋ชจํ„ฐ์˜ ํ™œ์„ฑ์„ ์ฆ๊ฐ€์‹œ์ผœ์•ผ ํ•œ๋‹ค. ์ด๋ฅผ ์œ„ํ•ด์„œ hypoxia response element (HRE) ๊ฒฐํ•ฉํ•ต์‹ฌ๋ถ€์œ„์„ ์žฌ์กฐํ•ฉํ•˜์—ฌ ํ”„๋กœ๋ชจํ„ฐ์˜ ํ™œ์„ฑ์„ ํ–ฅ์ƒ์‹œํ‚ฌ ์ˆ˜ ์žˆ๋Š”์ง€๋ฅผ ํ™•์ธํ•˜์˜€๋‹ค. ์žฌ์กฐํ•ฉ๋œ HRE ํ”„๋กœ๋ชจํ„ฐ ์ค‘, HRE30tr์ด ํฌํ•จ๋œ pdE1sp1A/HRE30tr/E2F/GFP ํ”Œ๋ผ์Šค๋ฏธ๋“œ๊ฐ€ ์ œ์ผ ํ–ฅ์ƒ๋œ ํ”„๋กœ๋ชจํ„ฐ ํ™œ์„ฑ์„ ๋ณด์—ฌ์ฃผ์—ˆ์œผ๋ฉฐ, ์ด๋ฅผ ํ† ๋Œ€๋กœ GFP๋ฅผ ๋ฐœํ˜„ํ•˜๋Š” ๋ณต์ œ ๋ถˆ๋Šฅ ์•„๋ฐ๋…ธ๋ฐ”์ด๋Ÿฌ์Šค๋ฅผ ์ด์šฉํ•œ ์‹คํ—˜์—์„œ๋„ HRE30tr/E2F/GFP๊ฐ€ ๊ฐ€์žฅ ํ–ฅ์ƒ๋œ ํ”„๋กœ๋ชจํ„ฐ ํ™œ์„ฑ์„ ๋ณด์—ฌ์ฃผ์—ˆ๋‹ค. ์ด ์—ฐ๊ตฌ๋ฅผ ๋ฐ”ํƒ•์œผ๋กœ ์žฌ์กฐํ•ฉ๋œ E2F-1 ํ”„๋กœ๋ชจํ„ฐ ์ค‘ ๊ฐ€์žฅ ์ข‹์€ ํ™œ์„ฑ์„ ๋ณด์ธ Ad-E2Ftr/E2F-d19, Ad-MYCtr/SP1tr/E2Ftr/E2F-d19, Ad-NFYtr/ATFtr/E2Ftr/E2F-d19, Ad-CUXtr/E2Ftr/E2F-d19์— ์ €์‚ฐ์†Œ ์กฐ๊ฑด์„ ๊ทน๋ณตํ•˜๊ธฐ ์œ„ํ•œ ์žฌ์กฐํ•ฉ ๋œ HRE ํ”„๋กœ๋ชจํ„ฐ ์ค‘ HRE30tr๋ฅผ ๊ฒฐํ•ฉํ•œ๋‹ค๋ฉด ํšจ๊ณผ์ ์ธ ์•”์„ธํฌ ์„ ํƒ์  ์‚ด์ƒ ์•„๋ฐ๋…ธ๋ฐ”์ด๋Ÿฌ์Šค๊ฐ€ ๋  ๊ฒƒ์œผ๋กœ ๊ธฐ๋Œ€๋œ๋‹ค.ope

    Evaluation of Antiangiogenic Effect Using Arterial Spin Labeling Perfusion MR Imaging in Rat Glioblastoma Model Treated with Bevacizumab

    No full text
    ํ•™์œ„๋…ผ๋ฌธ (๋ฐ•์‚ฌ)-- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› : ์˜๊ณผ๋Œ€ํ•™ ์˜ํ•™๊ณผ , 2016. 2. ํ•œ๋ฌธํฌ.Background and Purposeโ€“ I evaluated the antiangiogenic effect of bevacizumab in a rat glioblastoma (GBM) model based on arterial spin labeling (ASL) perfusion MR imaging compared to dynamic susceptibility contrast (DSC) perfusion MR imaging with histopathology. Materials and Methodsโ€“ The protocol was approved by the institutional animal care and use committee. DSC and ASL perfusion MR imaging were performed using a 9.4 T MR scanner in nude rats with GBM. Rats were randomly assigned in the following three groups: control, 3-days treatment, and 10-days treatment. One-way analysis of variances was used to compare perfusion parameters (e.g. normalized cerebral blood volume [nCBV] from DSC MR imaging, and normalized cerebral blood flow [nCBF] based on DSC MR imaging and ASL MR imaging) with microvessel area (MVA) on histology Pearsons correlations between perfusion parameters and MVA were determined. Resultsโ€“ MVA showed the consistent decrease with significant differences for the control, 3-days treatment, and 10-days treatment (P < 0.001). Consistent decreases with significant differences were also revealed in all perfusion parameters (P < 0.05 for all). In addition, nCBV and nCBF from DSC, and nCBF from ASL strongly correlated with MVA (R2 = 0.830, 0.755, and 0.739, respectively, P < 0.001 for all). Conclusionsโ€“ nCBF based on ASL has the potential to be used to evaluate the effect of antiangiogenic therapy on GBMs treated with bevacizumab with strong correlation with MVA.1. INTRODUCTION 1 2. MATERIALS AND METHODS 3 2.1. Tumor cell line 3 2.2. Animal model 3 2.3. MRI acquisition 4 2.4. MRI data analysis 6 2.5. Histological analysis 7 2.6. Statistical analysis 8 3. RESULTS 10 3.1. Analysis of tumor volume and perfusion parameters based on DSC or ASL perfusion MR imaging in all tumors 10 3.2. Analysis of tumor volume and perfusion parameters based on DSC and ASL perfusion MR imaging as well as MVA in tumors with available histology 11 4. DISCUSSION 24 5. REFERENCES 30 ๊ตญ๋ฌธ์ดˆ๋ก (Abstract in Korean) 37Docto

    Anomalous quadruple fluorescence and triplet state kinetics of [(9S3)Rh(ฮผ-SPh)โ‚ƒIrCp*](CIOโ‚„)โ‚‚

    No full text
    Thesis (master`s)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :ํ™”ํ•™๊ณผ ๋ฌผ๋ฆฌํ™”ํ•™์ „๊ณต,1998.Maste

    Effect of aprotinin on pulmonary vascular resistance after extracorporeal circulation

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(๋ฐ•์‚ฌ)--์„œ์šธ๋Œ€ํ•™๊ต :์˜ํ•™๊ณผ ํ‰๋ถ€์™ธ๊ณผํ•™ ์ „๊ณต,1999.Docto
    corecore